Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 1200
Summary
- Conditions
- Ulcerative Colitis
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials were able to roll-over in this trial to receive study medication until the end of 2021 or until marketing approval of RPC1063 for UC is obtained in their country, or until the Sponsor discontinues ...
The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials were able to roll-over in this trial to receive study medication until the end of 2021 or until marketing approval of RPC1063 for UC is obtained in their country, or until the Sponsor discontinues the development program, whichever comes first.
Tracking Information
- NCT #
- NCT02531126
- Collaborators
- Not Provided
- Investigators
- Study Director: AnnKatrin Petersen, M.D., MSc. Celgene Corporation